-
FRLN Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
-
ETFs
-
Insider
- Institutional
- Shorts
Freeline Therapeutics (FRLN)
Company Profile
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Cash on hand (at last report) | 48.61 mm | 48.61 mm | 48.61 mm | |||
Cash burn (monthly) | 23.49 mm | 7.58 mm | 6.62 mm | |||
Cash used (since last report) | 612.49 mm | 197.57 mm | 172.57 mm | |||
Cash remaining | -563.89 mm | -148.97 mm | -123.96 mm | |||
Runway (months of cash) | -24.0 | -19.7 | -18.7 |
13F holders | Current |
---|---|
Total holders | 11 |
Opened positions | 4 |
Closed positions | 2 |
Increased positions | 0 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 1.25 bn |
Total shares | 4.51 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Tetragon Financial Management | 4.00 mm | $0.00 |
Polygon Management | 266.67 k | $688.00 mm |
Tang Capital Management | 100.00 k | $258.00 mm |
MS Morgan Stanley | 34.86 k | $89.94 mm |
UBS UBS | 33.33 k | $86.00 mm |
Renaissance Technologies | 21.86 k | $56.00 k |
CHI Advisors | 21.67 k | $55.90 mm |
NTRS Northern Trust | 15.66 k | $40.40 mm |
Harbor Capital Advisors | 10.71 k | $27.63 mm |
Acadian Asset Management | 1.80 k | $4.00 k |